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, hyper t rophy 669 
, insulin deprivat ion 
669 
, mechanisms 669 
, ke tone bodies 669 
, phospha tase , alkaline 
713 
, S3-segment brush 
border 713 
, proximal 683 
, dysfunction marker 
683 
, a , -microglobulin 
683 
, sorbitol 669 
, triacylglycerol 669 
kind of quant i ty 
—, definit ion 245 
Kodak Ektachem 700 157 
kynuren ine 
—, a n d cholesterol A6 
—, and glomerulonephr i t i s 
A10 
—, and phosphol ip ids A6 
l abora to ry 
—, pa r ame te r 243 
, definition 243 
—, quant i t ies 243 
, terminology 243 
lactate 
—, p lasma 179 
, after exercise 179 
, in liver disease 179 
lactate dehydrogenase 
—, amnio t i c fluid 43 
, s torage condi t ions 43 
—, isoenzymes 43 
, amnio t ic fluid 43 
, s torage condi t ions 43 
—, p lasma 787 
, s t a n d a r d me thod 787 
, reference values 787 
—, serum 787 
, s t anda rd m e t h o d 787 
, reference values 787 
lactoferrin 
—, b ladder cancer 503 
- B C G therapy 503 
latex 
—, i m m u n o a s s a y 307 
, theophyl l ine 307 
, serum 307 
lavage 
—, broncho-a lveo la r 11, 785 
, pro te ins 11 
lavage fluid 
—, b ronchoa lveo la r 11, 785 
, elastase, neut rophi l 785 
. mul t iple t raumat ized 
pat ients 785 
leukaemia 
—, acute 127 
, phospho l ipase A2 127 
, p lasma 127 
—, drug 63 
, resistence 63 
leukocyte(s) 
—, act ivat ion 209 
, detect ion 209 
—, count 767 
, interference 767 
, sample preservat ion 
767 
, b lood gases 767 
lipaemia 
—, interference 15 
, a m m o n i a assay 15 
lipids 
- , accumula t ion 171 
, aor t ic int ima 171 
—, peroxidat ion 513 
- - , H D L 513 
, d iabetes mellitus 513 
- - , L D L 513 
, d iabetes mellitus 513 
—, peroxides 
- - , serum 119, 205, 847 
, co rona ry by-pass 
surgery 205 
- , serum 119, 847 
, renal t ransp lan ta t ion 
847 
l ipoamidase 
—, serum 119 
, act ivat ion 119 
, deficiency 119 
, inhibi t ion 119 
, subs t ra tes 119 
lipocalins 
—, a , -microglobul in 683 
, kidney 683 
l ipoproteins 
—, aggregat ion 171 
—, apol ipopro te in CI I /CI I I -
conta in ing 223 
, apol ipopro te in B 223 
, i m m unoenzy m o me-
tric assay 223 
—, modified 171 
, na tura l ly occuring 171 
, and lipid accumula-
tion 171 
, aor t ic intimal 171 
l iposomes 
—, amphoter ic in B 737 
, and permeabil i ty 737 
, cat ions 737 
, erythrocyte 737 
8-N-(Z),L-lipoyl)-L-lysine 119 
N - ^ L-lipoy l-/?-aminoben-
zoate 119 
lithium 
—, brain A8 
—, t ryp tophan influx A8 
liver 
—, cirrhosis 275 
, a lbumin 275 
, coagula t ion 275 
, intravascular 275 
, diffuse 275 
, D-d imer 275 
, fibrinolysis 275 
, pseudoCholinesterase 
275 
—, disease 179 
, exercise 179 
, ho rmones 179 
, p lasma 179 
, metaboli te 179 
, b lood 179 
, p lasma 179 
— , t ransplanta t ion 599 
, porphyr ia 599 
, acute 599 




—, t r yp tophan AI 1 
, p lasma A l l 
loading 
—, water 229 
, arginine8-vasopressin 
229 
low density l ipoproteins 171 
—, cholesterol 729 
, apol ipoprote in B-100 
729 
, defective 729 
—, cholesterol /phospholipid 
rat io 513 
, diabetes mellitus 513 
—, glycation 513 
, diabetes mellitus 513 
—, lipid peroxidat ion 513 
, diabetes mellitus 513 
—, oxidized 55 
, up t ake 55 
, degrada t ion 55 
, macrophages 55 
, macrophage 55 
, and Serotonins 55 
Z)-luciferyl-ß-£>-galactoside 
—, subst ra te 871 
, beta-galactosidase 871 
lutropin 
—, ur ine 297 
- - , ELISA 297 
g o n a d o t r o p i n , hu-






—, mal ignant 127 
, phosphol ipase A2 127 
, p lasma 127 
lysosomal enzymes 
—, plasma 595 
, quality control 595 
c a l i b r a t i o n mater ia l 
595 
ob-macroglobulin 
—, urine 707 
macromolecules 
—, selectivity 627 
, glomerulus 627 
macrophages 
- c h o l e s t e r o l cholesterol 
cs te r i f i ca t ion choles-
terol 
—, oxidized L D L 55 
, degradat ion 55 
, up take 55 
, and serotonin 55 
magnesium 
- e f f l u x 193 
—, p lasma 193 
, cystic fibrosis 193 
malignancies see also cancer, 
carc inoma, t u m o u r 
- C h i l d r e n 127 
, phosphol ipase A2 127 
, p lasma 127 
a-mannos idase 
—, plasma 595 
, cal ibrat ion mater ia l 
595 
marker see also t u m o u r 
marker 
—, angiotensinase A 663 
, urine 663 
, renal cell injury 663 
—, dipept idylpept idase IV 
663 
, urine 663 
, renal cell injury 663 
—, glomerular 617 
, urine 617 
—, proximal tubular dys-
function 683 
, a i -microglobul in 683 
—, tubular 617 
, urine 617 
mast cell 
- , t ryptase 871 
, bioluminescence i m m u -
noassay 871 
medul lary thyroid ca r c inoma 
see thyroid 
membrane 
- e r y t h r o c y t e 513, 737 
- - , fluidity 513 
, diabetes mellitus 513 
, fluorescence polar iza-
tion 513 
, permeabili ty 737 
c a t i o n s 737 
, protein glycation 513 
mercaptanes 
—, enzyme act ivators 119 
mesangial matr ix 
—, kidney 635 
XVII 
, d iabetes mell i tus 635 
metabol ic processes 
—, quant i t ies 901 
, as a function of t ime 
901 
- , uni ts 901 
metas tases 
- , bone 809 
, breast c a r c i n o m a 809 
, phospha t a se , a lka-
line 809 
, se rum 809 
m e t h o d 
- , definitive 157 
, cholesterol 157 
m e t h o d c o m p a r i s o n 
—, a m m o n i a 15 
—, cholesterol 153 
—, I g G subclass de t e rmina -
t ion 85 
—, pseudoCholinesterase 545 
- , theophyl l ine 307 
, se rum 307 
2-methoxy-4-(2 , -ni t rovinyl) -
phenyl-N-acetyl-ß-/)-glucos-
aminide 





, p h o s p h a t a s e a lkal ine 
247 
, s t anda rd m e t h o d 247 
4-methylumbel l i feryl-N-ace-
tyl-ß-Z)-glucosaminide 
—, subs t ra te 693 
, N-acetyl-ß-glucosamin-
idase 693 
met ro logy 
—, quan t i ty 245 
, definition 245 
, te rminology 245 
—, te rminology 243 
mic roa lbuminur i a 657 
a , -microglobul in 
—, ind ica tor 683 
, p rox imal t ubu l a r dys-
function 683 
—, ur ine 707 
micropar t ic le 
—, enhanced nephe lomet ry 
217 
, pro te ins 217 
, serum 217 
micro t i t re plates 
—, chemiluminescence detec-
t ion 209 
, whole b lood 209 
migra ine 
—, 5 -hydroxy t ryp tophan A7 
—, t r y p t o p h a n A 7 
milk 
—, biot in idase 119 
—, l ipoamidase 119 
minera ls 
—, me tabo l i sm 193 
, e ry throcytes 193 
, cystic fibrosis 193 
m i t o x a n t r o n e 63 
mo lds 
—, allergen 101 
m o n i t o r i n g 
—, b lood d o n o r s 717 
, hepat i t i s C virus 717 
—, breas t c a r c inoma 809 
—, d iabetes mell i tus 851 
, glycated pro te ins 851 
m o n o a m m o n i u m ura te 95 
m o n o c l o n a l an t ibod ies 
—, calci tonin 831 
m o o d 
—, a n d t r y p t o p h a n A2 
m u c u s 
—, bile 753 
, compos i t ion 753 
- , ga l lb ladder 753 
, p ro te ins 753 
, h igh molecular mass 
753 
, mucin-l ike 753 
mul t icent re eva lua t ion 
- , E k t a c h e m D T 6 0 547 
- , Hi tachi 747 881 
- , Ref lo t ron 547 
- , Seralyzer III 547 
mul t i layer film technology 
—, accuracy 239 
—, interferences 239 
m u r a m i c acid 
—, assay 141 
myeloperox idase 
—, and reactive oxygen spe-
cies 209 
—, b l adde r cancer 503 
, B C G therapy 503 
myoca rd ia l infarct ion 
—, acu te 823 
, size 823 
m y o c a r d i u m 
—, ischaemic 205 
, reperfusion 205 
, injury 205 
myoglob in 
—, serum 823 
, acu te myocard ia l in-
farct ion 823 
m^o-inosi tol 
—, k idney 607 
, ra t 607 
, d iabetes 607 
N A D H 
—, coenzyme 537 
, g lu t ama te dehydrogen-
ase 537 
, a m m o n i a assay 537 
N A D P H 
—, coenzyme 537 
, g lu t ama te dehydrogen-
ase 537 
, a m m o n i a assay 537 
N A D P H oxidase 
—, and reactive oxygen spe-
cies 209 
na t r iu re t ic pept ides see 
a t r ia l , b ra in 
neona t e s 
—, se rum 291 
, bi l irubin 291 
, spec topho tome t ry , 
direct 291 
, proficiency surveys 
291 
neopter in 
—, and cholesterol A 6 
—, and phosphol ip ids A6 
nephelometry 
- , latex- 307 
, theophyll ine 307 
—, micropart ic le enhanced 
217 
, proteins 217 
, serum 217 
nephron 
—, cathepsins 675 
, and pro te inur ia 675 
neph ropa thy 
- , diabetic 635, 651 , 657 
, and glycated a lbumin 
651 
nephrotoxici ty 
—, assessment 693 
, N-acetyl-ß-glucosamin-
idase 693 
neu rob la s toma 
—, phosphol ipase A2 127 
, p lasma 127 
neurokinin A 
—, cerebrospinal fluid 281 
, r ad io immunoassay 281 
neutrophi ls see also cells 
—, adherence 187 
—, chemiluminescence 187 
—, enzyme release 187 
—, functions 187 
, and ascorbic acid 187 
4-nitrophenyl-N-acetyl-ß-D-
glucosaminide 
—, subst ra te 693 
, N-acetyl-ß-glucosamin-
idase 693 
nomenc la tu re 
—, 6-phosphoglucona te de-
hydrogenase 47 
norepinephr ine 
—, p lasma 541 
—, saliva 541 
nutr i t ion 
—, t ryp tophan A 3 , A 4 
2 ' -5 ' -ol igoadenylate synthe-
tase 
—, peripheral b lood m o n o -
nuclear cells 521 
, after in ter feron-a 521 
, after interferon-ß 521 
—, serum 521 
, after in terferon-a 521 
, after interferon-ß 521 
osmolytes 
—, kidney 607 
, s t reptozotocin-diabetes 
607 
, rat 607 
oxygen 
—, derived radicals 187 
, and ascorbic acid 187 
—, reactive species 209 
pancreat i t is 
—, acute 263 
, phosphol ipase A 2 263 
, serum 263 
pa ramete r 
—, definition 243 
—, l abora to ry 243 
, terminology 243 
—, misuse 243 
—, use 243 
pa ra thy r in 
—, calcium regulation 815 
Parkinson's disease 
—, neurokin in A 281 
c e r e b r o s p i n a l fluid 281 
pa tho logy 
—, eosinophil ia-myalgia-syn-
d r o m e A13 
—, Spanish toxic oil syn-
d r o m e A17 
PC02 
- , b lood 767, 867 
, sample preservation 
767 
, s torage condi t ions 867 
, influence 867 
pentagas t r in 
—, s t imulat ion 831 




, subs t ra te 141 
, N-ace ty lmuramyl -L-
alanine amidase 141 
per formance 
—, analytical 881 
, assessment 881 
per iphera l b lood m o n o n u -
clear cells 
see cells, mononuc lea r 
permeabi l i ty 
—, erythrocyte 737 
, c a t i o n s 737 
, a l terat ion 737 
, amphoter ic in B li-
posomes 737 
—, g lomerular 627 
, erythrocytes 627 
, p l a sma proteins 627 
—, hydraul ic 627 
, erythrocytes 627 
, p l a sma proteins 627 
peroxida t ion 
—, lipid 205, 513 
, d iabetes mellitus 513 
peroxides 
- , lipid 205 
, se rum 205 
, co ronary by-pass 
surgery 205 
p H 
- , b lood 767, 867 
, sample preservation 
767 
, s torage condi t ions 867 
, influence 867 
phagocy te 
—, and reactive oxygen spe-
cies 209 
, functional state 209 
P h a r m a c i a C A P System 
- , I g E 101 
, allergen-specific 101 
, detect ion 101 
phenol indophenyl -N-ace ty l -
ß-i)-glucosaminide 
—, subs t ra te 693 
XVII I 
, N-acetyl-ß-glucosamin- - —, g lu tama te dehydrogen- - , p ro te ins 627, 851 —, serum 235 
idase 693 ase m e t h o d 537 , glycated 851 , inhib i tor 235 
phenylmethanesulphonyl flu- - , coenzyme 537 , permeabi l i ty 627 , N-benzyloxy car-
oride - —, interferences 15 , g lomerular 627 bonyl-prolyl-prol inal 
inhibi tor 119 - —, m e t h o d of compar i son —, t r y p t o p h a n AI 1 235 
, biot inidase 119 15 —, zinc 193 p ros t a t e 
, l ipoamidase 119 - —, selected method 15 , cystic fibrosis 193 —, acid phospha ta se 135 
phospha tase - - , ul trafi l trat ion 15 p02 , s e rum 135 
- , a lkal ine 21 , 43 , 247, 713, - , arginine8-vasopressin 229 - , b lood 767 , variability 135 
809 - —, rad io immunoassay 229 , sample preservat ion —, specific ant igen 135 
, amnio t ic fluid 43 — , water immersion 229 767 , se rum 135 
, s torage condi t ions 43 - , water loading 229 podophy l lo tox ins 63 , variability 135 - - , bone 809 - , CI inhibi tor 793 pollen p ro tease see proteinases 
, serum 809 -, carn i t ine , free 179 —, grass 101 prote in A , breast carc inoma - —, after exercise 179 , allergen 101 — ,eu rop ium- labe l l ed 529 
809 - , in liver disease 179 - , t r e e 101 , affinity 529 , intestinal 713 - , ca techolamines 541 , al lergen .101 , IgG 529 
, kidney tubule 713 - , Cortisol 531 po lymerase chain reac t ion pro te inases 
, S3-segment brush - —, enzyme immunoassay —, c D N A 717 —, cysteine 69 
border 713 531 , hepat i t i s C virus R N A , inhibi tors , endoge-
, se rum 21 — , a u t o m a t e d 531 717 neous 69 
, gallstone pat ients 21 - , e lastase 107, 503 p o l y t r a u m a —, g lomeru la r 641 
, s t anda rd method 247 — —, b ladder cancer 503 —, elastase, neu t rophi l 785 , glomerulosclerosis 641 
, N-methyl-D-gluca- - - - , B C G therapy 503 , b ronchoa lveo la r lavage , evolut ion 641 
mine buffer 247 - —, granulocyte 107 fluid 785 - i n h i b i t o r s 119, 793 phospha te see phosphorus - , h u m a n 107 po rphob i l i nogen , Na-/?-tosyl-L-lysine 
6-phosphogluconate dehy- - , enzymes 595 —, ur ine 599 ch loromethy l ke tone 
drogenase - —, lysosomal 595 po rphob i l inogen deaminase 119 
—, nomencla ture 47 - , qual i ty control 595 —, e ry throcytes 599 , N- tosyl -L-phenyla la-
phosphol ipase A2 - , ca l ibrat ion mate- p o r p h y r i a nine chloromethyl ke-
—, ascitic fluid 263 rial 595 - , acu te 599 tone 119 
—, immunob lo t t ing 263 - , ep inephr ine 541 , amino laevu l ina te dehy- , phenylmethanesu l -
—, p lasma 127 - , fatty acids, free 179 d ra t a se deficiency 599 phony l fluoride 119 
c h i l d r e n 127 — —, after exercise 179 , liver t r ansp lan ta t ion , se rum 793 
, mal ignant disorders - , in liver disease 179 599 , C I inhibi tor 793 
127 - , fibrinogen 745 p o r p h y r i n s pro te in G 
- , serum 111, 263 - —, reference limits 745 —, e ry throcytes 599 — ,eu rop ium- labe l l ed 529 
, character izat ion 111 - , fibronectin 503, 847 —, ur ine 599 , affinity 529 
, fluoroimmunoassay - —, b ladder cancer 503 po tas s ium , IgG 529 
263 - - - , B C G therapy 503 —, amnio t i c fluid 43 prote in H C 
, t ime resolved 263 - —, renal t ransp lan t pa- , s to rage condi t ions 43 —, see a , -microglobul in 683 
, pancreat i t is , acute t ients 847 —, permeabi l i ty 737 pro te ins 
263 - , g lucagon 179 , e ry throcyte 737 —, broncho-a lveo la r lavage 
, sepsis 263 - —, after exercise 179 pract icabi l i ty 11 
, isoenzymes 111 - , in liver disease 179 - , Hi tachi 747 881 , recovery 11 
. isolation 111 - , H D L 513 predict ive value , s t andard i sa t ion 11 
, purification 111 — , insulin 179 —, t u m o u r marke r s 809 - , glycated 851 
phosphol ipids - —, after exercise 179 , b reas t ca rc inoma 809 , p l a sma 851 
—, and kynurenine A6 - , in liver disease 179 pred ic to r , d iabe tes mellitus 851 
—, and neopter in A6 - , i r o n 193 —, card iovascu la r disease , se rum 851 
—, and pyr idoxal-5-phos- - —, cystic fibrosis 193 745 , d iabe tes melli tus 851 
pha te A6 - , lac ta te 179 , f ibrinogen 745 —, high molecular mass 753 
phosphorus - —, after exercise 179 preserva t ion , mucin- l ike 753 
—, inorganic 43 - , in liver disease 179 - , sample 75, 135, 767 , ga l lb ladder mucus 
, amnio t ic fluid 43 - , lac ta te dehydrogenase , formic acid 75 753 
, s torage condi t ions 43 787 , p ros ta t i c acid p h o s p h a - —, p lasma 627 
- , a c i d 135 - —, s t anda rd me thod 787 tase 135 , permeabi l i ty 627 
. pros ta t ic 135 - , reference values 787 , p ros t a t e specific an- , g lomeru la r 627 
, serum 135 — , lactoferrin 503 tigen 135 —, serum 217 
, variability 135 - - , b ladder cancer 503 prick m e t h o d —, abso rp t i on 675 
—, serum 815 - - - , B C G therapy 503 - , skin test 101 , k idney 675 
. after calcium adminis- -, L D L 513 processes , and cathepsins 675 
t ra t ion 815 - , magnes ium 193 —, related quant i t ies 901 —, conjugates 39 
picolinic acid - —, cystic fibrosis 193 proficiency surveys , bi l irubin 39 
—, and i m m u n e system A10 — , myeloperoxidase 503 - , b i l i rubin 291 - , d i e t 641 
plasma - - , b ladder cancer 503 proinsul in , a n d chronic renal fail-
—, acetyl-carnitine 179 - - - , B C G therapy 503 —, intact 27 ure 641 
.a f te r exercise 179 - , norep inephr ine 541 , i m m u n o e n z y m o m e t r i c —, excret ion 651 
, in liver disease 179 - , phospho l ipase A2 127 assay 27 , k idney 651 
—, amino acids A5 - - C h i l d r e n 127 , sensitive amplified , p a t h o m e c h a n i s m 651 
. var ia t ions A5 - , mal ignant disorders 27 —, pa t t e rn 707 
—, a m m o n i a 15, 537 127 prolyl endopep t idase , ur ine 707 
X I X 
, h aema tu r i a 707 
, charac ter iza t ion 
707 
, p ro te inur ia 707 
, charac te r iza t ion 
707 
total 21 
, se rum 21 
, gal ls tone pa t ients 21 
—, vo lume displacement ef-
fect 861 
pro te inur ia 
—, cathepsins 675 
, nephron 675 
—, charac te r iza t ion 707 
, pro te in pa t te rn 707 
, urine 707 
—, a , -microglobul in 683 
pseudoCholinesterase 
—, atypical var ian ts 545 
, assay 545 
, m e t h o d c o m p a r i s o n 
545 
, reagent compos i t ion 
545 
, influence 545 
— ^cirrhosis 275 
, liver 275 
Pseudomonas aeruginosa 
—, elastase 285 
, assay 285 
, enzymat ic 285 
, immunologica l 285 
, p roduc t ion 285 
pur ine bases 
— c e r e b r o s p i n a l fluid 761 
, chi ldren 761 
pur ine nucleot ides 
— C e r e b r o s p i n a l fluid 761 
, children 761 
pyr idoxa l -5 -phospha te 
—, and cholesterol A6 
—, and phosphol ip ids A6 
pyr imidine bases 
— c e r e b r o s p i n a l bases 761 
, children 761 
qual i ty 
—, character is t ics 881 
, acceptance criteria 881 
—, cont ro l 595 
, enzymes 595 
, lysosomal 595 
, ca l ibra t ion ma te -
rial 595 
, p l a sma 595 
—, specifications 311 
, imprecision 311 
, analyt ical systems 
311 
Conical chemis t ry 
311 
, inaccuracy 311 
, analyt ical systems 
311 
, clinical chemist ry 
311 
qual i ty cont ro l 
—, b iopharmaceu t i ca l s A21 
—, thin layer c h r o m a t o g r a -
phy A20 
—, t r y p t o p h a n product ion 
A 1 8 , A19 
quant i t i es 
- . d e f i n i t i o n 245, 901 
—, for metabol ic processes 
901 
, as a function of time 
901 
—, l abo ra to ry 243 
, definit ion 243 
—, met ro logy 245 
radial immunodiffusion 
- , I g G 85 
, serum 85 
, subclass de termina-
tion 85 
radicals 
—, oxygen derived 187 
, and ascorbic acid 187 
r a d i o i m m u n o a s s a y 
—, arginine8-vasopressin 229 
, p l a sma 229 
—, atr ial na t r iure t ic peptides 
837 
—, brain nat r iure t ic pept ides 
837 
- C G M P 837 
, atr ial na t r iure t ic pep-
tides 837 
, b ioassay 837 
—, neurok in in A 281 
, cerebrospinal fluid 281 
r a d i o l a b e l e d receptor assay 
—, y -aminobu ty r i c acid 271 
rat 
—, ar thr i t i s AI 1 
rate 
—, of convers ion 901 
—, of react ion 901 
ra t io 
—, HDL-cho les te ro l / to ta l 
cholesterol 153 
rats 
—, low sod ium 647 
, g lomeru la r hyperfiltra-
tion 647 
, atr ial natr iuret ic 
pept ide 647 
, and adenosine de-
aminase 647 
—, osmolytes 607 
, kidney 607 
, s t reptozotocin diabe-
tes 607 
react ion rate 901 
reactive oxygen state 209 
reagent compar i son 
—, declara t ion 545 
receptor 
—, r a d i o l a b e l e d 271 
, assay 271 
, y -aminobutyr ic acid 
271 
—, t r y p t o p h a n A2 
reference intervals 
—, Cholinesterase 163 
, serum 163 
, s t a n d a r d method 163 
reference limits 
—, fibrinogen 745 
, p l a sma 745 
reference material 
—, cholesterol 157 
reference ranges 
—, fructosamine 33 
, ch i ldhood 33 
—, glucose 33 
, chi ldhood 33 
- , H b A l c 33 
, ch i ldhood 33 
reference values 
—, lactate dehydrogenase 
787 
, p lasma 787 
, s t andard me thod 787 
, serum 787 
, s t andard me thod 787 
Refletron® 
- , cholesterol 153 
—, creat inine 51 
, accuracy 51 
—, mult icentre evaluat ion 
547 
regulation 
—, calcium 815 
renal failure 
—, chronic 641 
, and protein 641 
, diet 641 
reperfusion 
—, myoca rd ium 205 
, ischaemic 205 
, injury 205 
resistence 
—, d rug 63 
, leukaemia 63 
reverse t ranscr ip t ion 
- , virus R N A 717 
, hepati t is C 717 
r h a b d o m y o s a r c o m a 
—, phosphol ipase A 2 127 
, p lasma 127 
ribonucleic acid 
—, hepatit is C virus 717 
, serum 717 
risk 
- , profile 223 
, coronary hear t disease 
223 
safety 
—, t ryp tophan A18 
saliva 
—, ca techolamines 541 
—, epinephr ine 541 
- , I g A 81 
, collection me thod 81 
—, norep inephr ine 541 
salivette 81 
sample 
—, collection 81 
, saliva 81 
, IgA 81 
— p r e s e r v a t i o n 135, 75 
, formic acid 75 
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Summary: A highly sensitive radioimmunoassay for arginine8-vasopressin (argipressin; INN) measurement 
was developed using Amberlite XAD 2 resin columns to extract arginine8-vasopressin from acidified human 
plasma. Arginine8-vasopressin was determined by a rapid radioimmunoassay method (2 x 20 h) using a 
specific antibody and 125I-labelled antigen. The bound fraction was separated by adsorption of the free fraction 
onto bovine serum albumin-coated charcoal; this resulted in low unspecific binding of less than 2%. Recovery 
experiments in the physiological range resulted in a mean (± SEM) recovery of 88 + 3%. The radioimmu-
noassay consistently yielded a detection limit of 0.3 ng/1 (ED90) and a mean 50% binding intercept (ED50) of 
3.5 ng/1. Arginine8-vasopressin immunoreactivity was characterized by reverse-phase high performance liquid 
chromatography, which confirmed the specificity of the assay. Serial plasma dilution curves paralleled the 
standard curve. The intra- and inter-assay variations were 9.4% and 15%, respectively. Arginine8-vasopressin 
concentrations in healthy subjects were determined in normal hydration status (2.2 + 0.3 ng/1; n = 11), as 
well as during suppression by water immersion (1.5 + 0.2 ng/1; n = 11) or by water loading (1.6 ± 0.2 ng/1; 
n = 8). Thus, this assay allows for a sensitive, accurate and rapid quantification of plasma arginine8-
vasopressin concentrations. 
Introduction 
Alterations of arginine8-vasopressin plasma concen-
trations seem to be involved in the abnormal water 
handling that is present in several diseases. Thus, 
investigations in patients with congestive heart failure 
(1 — 3), hyperaldosteronism (4) or syndrome of inap-
propriate antidiuresis (5, 6) demonstrated abnormal 
arginine8-vasopressin secretion as a determinant of 
impaired water balance. Furthermore, any investiga-
tion of the physiological regulation of water homeo-
stasis should comprise determination of arginine8-
vasopressin plasma concentrations (7, 8). Therefore, 
an accurate determination of arginine8-vasopressin is 
important for both physiological and clinical pur-
poses. Efforts to obtain an exact measurement of the 
rather low plasma concentrations of arginine8-vaso-
pressin by radioimmunoassay have been hampered by 
the presence of different interfering factors which are 
still only partially characterized. Thus, limited speci-
ficity is inherent in the methods using direct radioim-
munoassay for arginine8-vasopressinin plasma (9,10), 
necessitating plasma extraction before radioimmu-
noassay of the neurohypophyseal peptide. Different 
extraction procedures have been used, including the 
use of acetone and petroleum ether (11, 12), cold 
ethanol (13) or Bentonite (14), but they show poor 
and variable recoveries (11, 13). Furthermore, several 
radioimmunoassays for arginine8-vasopressin involve 
complicated separation techniques, and in order to 
obtain adequate sensitivity they employ incubation 
periods of up to 7 days (9, 15). 
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Therefore we have developed a simple, accurate and 
rapid method for determining arginine8-vasopressin 
following extraction from plasma. The method has a 
very low detection limit. 
Materials and Methods 
M a t e r i a l 
Sample preparation and extraction 
Blood was collected in d isodium ethylenediaminete t raaceta te 
coated tubes and immediately centrifuged at 2000 g for 10 min 
at 4 °C. The p lasma was removed, t reated with phenylmethyl-
sulphonylf luoride (5 mmol/1) and acidified with acetic acid to 
p H 5.5 (2.5 mol/1). F o r extract ion the p lasma samples were 
adsorbed as 1 ml a l iquots to activated Amberl i te X A D 2 resin 
(Serva, Heidelberg, G e r m a n y ) c h r o m a t o g r a p h y co lumns (Bio-
Rad Labora tor ies , R i c h m o n d , CA 94804) followed by washing 
with tr if luoroacetic acid (1 mmol/1). The elution was performed 
using a mobile phase consist ing of 1 mol/1 acetonitri le (80%) 
and 1 mmol/1 trifluoroacetic acid (20%) . T h e lyophilized sam-
ples were reconst i tuted in 300 ul assay buffer I. 
Recovery 
Recovery experiments were performed by parallel extract ion of 
1, 2, 4 and 8 p g synthetic arginine8-vasopressin (Bissendorf 
Biochemicals G m b H , Hannover , Ge rmany) added to 1 ml ali-
quo t s of different p lasma samples. 
Assay buffers 
Two assay buffers were used in this rad io immunoassay . 
Assay buffer I was prepared with 20 g/1 of bovine serum 
a lbumin in 50 mmol/1 phospha t e buffer (pH 7.4) conta in ing 
5 mmol/1 phenylmethylsulphonylf luoride, 0.1 mol/1 sodium 
chloride, 10 mmol/1 d isodium ethylenediaminete t raaceta te a n d 
0.1 mol/1 Tri ton X-100. After incubat ion for 4 h at 56 °C the 
buffer was diluted 10 fold. Neomyc in sulphate (2 g/1) and so-
d ium azide (1 g/1) were then added and the p H adjusted to 7.4. 
F o r assay buffer II dissolved gelatine (1 g/1) was added to 20 
mmol/1 phospha te buffer conta in ing 0.15 mol/1 sodium chloride, 
0.1 g/1 bovine serum a lbumin and 0.1 g/1 thimerosal . Thereafter 
the p H was adjusted with sodium hydroxide (10 mol/1) to 7.4. 
Standard curve 
K n o w n a m o u n t s of synthetic arginine8-vasopressin were serially 
diluted ranging from 80 to 0.08 ng/1 in assay buffer I. 
M e t h o d s 
Assay protocol 
Polyclonal an t ibody (Nol 728-6), generated against synthetic 
arginine8-vasopressin bovine thyroglobul in conjugates in r ab -
bits (16), was diluted to bind a b o u t a third of the total r ad io -
labelled antigen added in the absence of unlabelled ant igen. 
Ant i serum (100 ul, end dilut ion 1 : 50000) was added to s tand-
ards and extracted ant igens. Incuba t ion was carried out in 
polypropylene tubes for 20 h at 4°C. Then, 1.6 pg / tube I 2 5I-
labelled arginine8-vasopressin (Amersham Braunschweig, Ger -
many, 74 T B q / m m o l (2000 Ci /mmol) ; 100 ul) was added , fol-
lowed by incubat ion at 4 °C for a further 20 h. 
In order to determine cross-reactivities of the an t ibody with 
o ther peptides, s t andard curves of the rad io immunoassay were 
performed with ocytocin, atr ial natr iuret ic peptide, angiotensin 
II and lysine8-vasopressin, respectively, instead of unlabelled 
argini ne8-vasopressin. 
Separation 
Separa t ion was performed by add ing 500 ul of bovine serum 
a lbumin-coated charcoal ( 2 9 % / 7 1 % , by weight) dissolved in 
assay buffer II . After 10 min, s t andards and samples were 
centrifuged at 4 °C for 10 min at 2000 g and the supe rna tan t 
was counted ( L K B , Turku, F in land , 8 0 % efficiency) in tripli-
cate. 
Non-specific binding was de termined by performing the ra-
d io immunoassay wi thout an t ibody (n = 9). 
Reverse-phase-HPLC 
Arginine8-vasopressin immunoreact iv i ty was character ized by 
reverse-phase high per formance liquid c h r o m a t o g r a p h y 
(n = 6). F o r cal ibrat ion a s t andard of 200 pg synthetic 
arginine8-vasopressin was dissolved in 250 ul acetoni tr i le and 
submit ted to reverse-phase high performance l iquid c h r o m a -
tography (C 8 -ul t rapore T M co lumn [5 um], Beckman San Ra-
m o n , U . S . A . ) . S tandard and extracted samples were eluted 
with a linear gradient from 1 5 % — 4 5 % acetonitrile in 1 mmol/1 
tr if luoroacetic acid in 35 min (flow rate 0.5 ml /min, fraction 
size 0.5 ml / tube) . Subsequently, the ho rmone conten ts of the 
fractions were measured by rad io immunoassay . 
Water immersion 
Water immers ion was performed as described in detai l elsewhere 
(17 — 19). Briefly, following 1 h in the sitting posi t ion a t room 
tempera tu re (28 °C) beside the water thank, 11 heal thy, nor-
mally hyd ra ted subjects were immersed to the level of the neck 
into the rmoneu t ra l water (34.5 °C) for 1 h followed by 1 h 
outs ide the tank . Blood samples were taken immediately before, 
after 1 h immers ion and 1 h after exiting the t ank . 
Water loading 
After a n overnight fast (16 h) b lood samples (basal value) were 
taken from 8 heal thy volunteers . Thereafter the subjects were 
orally water loaded with 20 ml /kg body weight within 30 min 
and b lood samples were taken 1 h later. 
All d a t a are given as mean ± s tandard error of the mean . 
Significance of differences was tested by the Student t-test. 
Results 
Recovery experiments (n = 11) with physiological 
concentrations of synthetic arginine8-vasopressin 
added to different plasma samples prior to extraction 
showed a linear relationship between added and de-
termined arginine8-vasopressin concentration with a 
mean recovery of 88 + 3%. Figure 1 illustrates a 
typical standard curve for the radioimmunoassay of 
arginine8-vasopressin with the 50% binding intercept 
(ED50) at 3.5 ng/1 and a lower detection limit (ED90) 
of 0.3 ng/1 (n = 8). Serial dilutions of 0.5, 1, 2 and 
4 ml plasma paralleled the standard curve. The intra-
assay coefficient of variation (n = 8) averaged 9.4%, 
the inter-assay coefficient of variation (n = 8) was 
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Plasma [ml] 
o H 1 1 — i — i 1 1 1 — i — 
0.0 0.1 0.6 1 2 5 20 50 80 
Arg 8 -vasopressin [ng/ l ] 
Fig. 1. Typical s t a n d a r d curve with a low detection limit (ED 9 0 
= 0.3 ng/1, E D 5 0 = 3.5 ng/1 and E D l 0 = 58.1 ng/1). 
Serial d i lu t ions of p lasma paralleled the s t anda rd curve, 
conf i rming the accura te measurement of p lasma sam-
ples. 
Fraction no. 
Fig. 2. Coe lu t ion of arginine8-vasopressin immunoreact iv i ty of 
an ext rac ted p lasma sample with synthetic arginine8-
vasopress in by reverse-phase high per formance liquid 
c h r o m a t o g r a p h y analysis, confirming the specificity of 
the assay. 
15%. No cross-reactivity of the anti-arginine8-vaso-
pressin antibody to ocytocin, atrial natriuretic peptide 
and angiotensin II could be observed. The cross-
reactivity to lysine8-vasopressin was 3%. The non-
specific binding was less than 2%. 
Reverse-phase high performance liquid chromato-
graphy analysis revealed coelution of immunoreactive 
arginine8-vasopressin with synthetic arginine8-vaso-
pressin as a single peak (fig. 2). 
Central volume stimulation by 1 h head-out water 
immersion in 11 healthy subjects produced a signifi-
cant drop (2.2 ± 0.3 vs. 1.5 ± 0.2 ng/1, p < 0.05) of 
arginine8-vasopressin plasma concentrations. In the 
recovery period, arginine8-vasopressin returned to 
baseline concentrations (1.5 ± 0.2 vs. 2.0 + 0.3 ng/1, 
p < 0.05). Oral water loading of 8 healthy subjects 
significantly decreased arginine8-vasopressin plasma 
concentrations (2.0 ± 0.2 vs. 1.6 ± 0.2 ng/1, 
p < 0.05) as well as plasma osmolality (282 + 5.5 vs. 
274 ± 4.4 mosmol/kg, p < 0.05). Arginine8-vaso-
pressin plasma concentrations were significantly cor-
related with plasma osmolality (r = 0.83, p < 0.01). 
Discussion 
Due to the very low plasma concentration of 
arginine8-vasopressin and the presence of inade-
quately characterized interfering factors, the devel-
opment of a sensitive and specific radioimmunoassay 
for arginine8-vasopressin has proved to be more dif-
ficult than for many other peptides (9). 
In contrast to a variety of less specific antisera raised 
for vasopressin determination (20 — 23), we used a 
highly specific one (16). Due to the specificity of this 
antibody (confirmed by cross-reactivity experiments 
and high performance liquid chromatography analy-
sis), the extraction procedure was simpler than those 
reported previously for other methods. The usefulness 
of this Amberlite XAD 2 resin extraction procedure 
was confirmed by the linear relationship between 
added and measured arginine8-vasopressin concentra-
tion in the recovery experiments, as well as by a 
reliable mean recovery rate of 88%. 
Tab. 1. Arginine8-vasopressin assays described by different au tho r s 
Au thor Lower detect ion E D 5 0 Mean Incuba t ion H P L C 
limit recovery t ime analysis 
Bichel, D. G. (24) 0.5 ng/1 1.2 pg / tube* 102% 120 h + 
Bie, P. (25) 0.5 pg / tube* 8.5 pg / tube* 7 2 % -
Bodola, K (26) 0.4 ng/1 4.6 ng/1 8 0 % 32 h -
Durr, J. A. (27) 0.2 pg / tube* 5.0 pg / tube* 1 0 3 % 96 h -
Fyhrquist, F. (10) 1.2 ng/1 8.3 ng/1 9 6 % 168 h — 
Gerbes, A. L. ( this paper ) 0.3 ng/1 3.5 ng/1 8 8 % 40 h + Husain, M. K. (11) 0.1 ng/1 0.8 ng/1 6 8 % 120 h -Keil, L. C. (28) 1.6 ng/1 4.2 pg / tube* 1.1 pg / t ube* 6 4 % 134 h -Robertson, G. L. (9) 0.5 ng/1 9 6 % 168 h -
Ross, M. G. (29) 0.8 ng/1 4.0 ng/1 7 0 % -
Samson, W. K. (16) 1.0 pg / tube* 25.0 pg / tube* 8 0 % 96 h -
Skowsky, W. R. (14) 0.7 ng/1 10.8 ng/1 8 4 % 120 h 
* where abso lu t e concent ra t ions could not be derived, d a t a are adop ted as specified in the cited publ icat ion 
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The radioimmunoassay consistently yielded a detec-
tion limit of 0.3 ng/1 after only 2 x 20 h of incubation. 
In other methods, much longer incubation times are 
needed to obtain a comparably low detection limit 
(tab. 1). The present assay can therefore be considered 
as both highly sensitive, and more rapid than other 
assays. 
Arginine8-vasopressin immunoreactivity determined 
in plasma was characterized by reverse-phase high 
performance liquid chromatography. Immunoreactive 
arginine8-vasopressin was coeluted with synthetic 
arginine8-vasopressin as a single peak, confirming the 
specificity of the assay. 
Isoosmotic arginine8-vasopressin suppression by cen-
tral volume stimulation during water immersion (30, 
31) was clearly demonstrated in accordance with the 
findings of other groups, supporting the concept of 
inhibition of arginine8-vasopressin secretion by acute 
atrial distension (32, 33). 
Hypoosmolality as an osmotic stimulus of arginine8-
vasopressin suppression (9) was confirmed by a sig-
nificant decrease of plasma arginine8-vasopressin con-
centrations and plasma osmolality after oral water 
loading. Both quantities were closely correlated. 
In conclusion, this radioimmunoassay for arginine8-
vasopressin can be considered as highly sensitive, ac-
curate and rapid, and it can be easily established in 
any suitably equipped laboratory. 
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